Day: January 5, 2023

Figure 1 White Gold Property OverviewFigure 2 2022 Ryan’s Surprise DrillingFigure 3 WHTRS22D029 Cross SectionFigure 4 WHTRS22D029 Core 266.50m to 278mFigure 5 Ryan’s Surprise Gold Zones Isometric ModelTORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) — White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the “Company”) is pleased to report positive assay results for its 2022 diamond drilling program on the Ryan’s Surprise target, which is located approximately 2km west of its flagship Golden Saddle and Arc deposits and 11km south of the Company’s VG deposit on the Ryan’s Trend, a 6.5km long x 1km wide north-northwest trend of anomalous gold and arsenic in soils (Figure 1). Hole WHTRS22D029 encountered several zones of significant gold mineralization including 5.34 g/t Au over 10.85m and represents a 50m extension...

– Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR – – Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021 – – Cash and investments of approximately $144 million as of December 31, 2022 – WATERTOWN, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced a business update and key 2023 clinical timelines for its lead product candidate, EYP-1901. EYP-1901 is an investigational sustained delivery product for serious retinal diseases that uses a bioerodible...

Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer’s disease is progressing with targeted enrollment completion in mid-2023 and topline data in early 2024 ATH-1105 candidate for amyotrophic lateral sclerosis (ALS) is targeted for IND filing in 2023 BOTHELL, Wash., Jan. 05, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided an update on its pipeline development programs and outlook for 2023. “Our dedication to advancing new therapeutics to impact neurodegenerative diseases remains...

All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM).Company-sponsored Phase 2 multi-center clinical trial of autologous INB-400 gamma-delta T cells in newly diagnosed GBM patients to start enrollment by Q3 2023.Submission of Investigational New Drug Application (IND) for the Phase 1b trial of INB-410, a genetically modified allogeneic gamma-delta T cell therapy in relapsed and newly diagnosed GBM anticipated in 2H 2023.Announcement of a new solid tumor indication with relevant data at a scientific conference in 1H 2023.NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq:...

Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today summarized accomplishments for 2022 and outlined anticipated key milestones for 2023. The Company is expected to begin its Phase 3 trial in PKU in the first half of this year. In addition, SYNB1353 was granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for the potential treatment of HCU. RPDD is granted to drugs which are under development for rare childhood...

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that the management team will participate and present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 PM PST. Event: 41st Annual J.P. Morgan Healthcare Conference Date: Thursday, January 12, 2023 Time: 12:00 PM PST A live audio webcast of the conference presentation will be available online on the investor relations page of the Company’s website at https://ir.asensus.com/events-and-presentations. Replays of the webcasts will be archived on the website for approximately 30 days. About Asensus Surgical, Inc. Asensus...

CALGARY, Alberta, Jan. 05, 2023 (GLOBE NEWSWIRE) — Precision Drilling Corporation (“Precision” or the “Company”) (TSX:PD; NYSE:PDS) provides a series of positive announcements including: 1) 2022 debt repayment and year-end liquidity update; 2) capital allocation framework update; and 3) operations update for drilling activity, Alpha™ technologies and EverGreen™ environmental solutions. 2022 Debt Repayment and Year-End Liquidity Update Precision reduced total debt by $106 million in 2022, exceeding its $75 million debt reduction goal. As of December 31, 2022, Precision’s outstanding debt obligations included:US$44 million – senior credit facility due June 18, 2025 US$348 million – 7.125% senior notes due January 15, 2026 US$400 million – 6.875% senior notes due June 15, 2029In addition, Precision had approximately...

HONG KONG, Jan. 05, 2023 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce solutions for large parcel merchandise, announced today the appointments of Zoe Wong as General Counsel, and Anthony Garcia as Vice President of Logistics, respectively. Ms. Wong has joined the Company in January 2023. Prior to joining the Company, Ms. Wong was a corporate associate at the Hong Kong office of Latham & Watkins. Qualified in both New York, U.S. and Hong Kong, Ms. Wong possessed years of experience in advising corporates and financial institutions on various capital markets and U.S. securities laws matters. In her new role, Ms. Wong will provide counsel to the Company on public company matters, compliance and other general corporate matters. Mr. Garcia...

Figure 1 Mining Production ProfileFigure 2 Kwanika Central Open PitFigure 3 Kwanika Central UndergroundFigure 4 Stardust UndergroundFigure 5 Kwanika South Open PitFigure 6 Process Flow DiagramVANCOUVER, British Columbia, Jan. 05, 2023 (GLOBE NEWSWIRE) — NorthWest Copper Corp. (“NorthWest” or “the Company”) (TSX-V: NWST) (OTCQX: NWCCF) is pleased to announce the results of the preliminary economic assessment (“2023 PEA”), conducted by Ausenco Engineering Canada Inc. (“Ausenco”) and Mining Plus Canada Consulting Ltd (“Mining Plus”), on its 100% owned Kwanika-Stardust Project comprising the Kwanika and Stardust deposits (the “Project”). This represents the first technical and economic evaluation of the combined deposits outlining a robust project with manageable initial capital cost and multiple opportunities for...